Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
ZURAHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Ki
Zura Bio Reports Business Updates and Outlook for 2026
ZURAHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026. “We are excited to enter 2026, as we get closer to two potentially transformative readouts over the next 18 months for tibulizumab, starting with anticipated
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
ZURAHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor me
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
ZURAHENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “The second quarter of 2025 marked continued progress across our clinical programs and organizational goals,” said Robert Li
Zura Bio Launches Global Phase 2 TibuSHIELD Study To Evaluate Tibulizumab In Adults With Hidradenitis Suppurativa, Topline Results For Primary Efficacy Endpoint At Week 16, Along With Key Secondary And Exploratory Outcomes, Are Anticipated In Third Quarte
ZURAOppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $17
ZURAZura Bio Q1 EPS $(0.19) Misses $(0.15) Estimate
ZURAHC Wainwright & Co. Maintains Neutral on Zura Bio, Lowers Price Target to $3
ZURAOppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $19
ZURAGuggenheim Reiterates Buy on Zura Bio, Maintains $15 Price Target
ZURAChardan Capital Maintains Buy on Zura Bio, Lowers Price Target to $10
ZURAZura Bio Posts FY24 Net Loss Of $0.60
ZURAZura Bio FY2024 GAAP EPS Of $(0.60) Vs. $(2.09) YoY, Cash And Cash Equivalents Were $176.5M As Of December 31, 2024, Expected To Provide Cash Runway Through 2027
ZURAHC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target
ZURAHC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target
ZURAZura Bio Announces Submission Of Protocol To FDA For Phase 2 Study Of Tibulizumab In Adults With Systemic Sclerosis
ZURALeerink Partners Initiates Coverage On Zura Bio with Outperform Rating, Announces Price Target of $15
ZURA